Clinical calculators and predictors are now commonly used in clinical practice to predict most accurate clinical outcome and provide guidance for appropriate therapy. One of the most used calculator is Onco-assist. This study was conducted to compare onco-assist prediction of the patients diagnosed with colon cancer Stage I, II and III. Data was retrospectively collected from 88 patients of colon cancer diagnosed over the period of 11 years (2008 to 2018) and registered at Nuclear Institute of medicine and radiotherapy (NIMRA), Hospital, Jamshoro Sindh. These patients received primary surgical therapy without any neo-adjuvant systemic chemotherapy. Survival assessed on onco-assist prediction algorithm using the defined parameters and compared with the actual survival according to the grade of the tumour. The clinical calculator onco-assist incorporated seven variables: gender, age number of lymph nodes examined, number of tumor-involved lymph nodes, T = (1-4), grade (low / high), adjuvant chemo received (yes / no) if yes then only 5FU or 5FU plus Oxaliplatin based. Onco-assist predicted five-year survival rate in well differentiated tumours with and without chemotherapy as 84% and 80% respectively, in moderately differentiated tumour with and without chemotherapy as 78% and 76% respectively. For poorly differentiated tumours the predicted survival rate with and without chemotherapy was 73%. While actual achieved survival was 35%, 52% and 17% for well, moderately and poorly differentiated cancers. This clinical calculator onco-assist includes limited parameters and limited adjuvant therapy options thus the prediction of cancer survival following surgery in stage I –III colon cancer does not appear to accurately predict outcome in Asian population.

No abstract

No abstract

Colon cancer is among the most commonly occurring cancers globally and is linked with a poor prognosis. The incidence and prevalence of cancer is expected to rise more in the upcoming years. Right-sided colon cancer reportedly related with poorer survival as compared to the left-sided cancer. This study was conducted to compare both-sided cancers in the Pakistani population. A retrospective analysis of the case files was conducted, including 119 colon cancer patients (i.e. Right colon cancer=41, left colon cancer=78). Left-sided colon cancer showed a lower grade and less rate of metastases. The results showed no significant influence of sidedness on survival outcome, though there was a non-significance difference in favor of right colon cancer.  Further studies are required to explore biological differences in cancers arising from both sides of colon.

e15514 Background: Colorectal cancer (CRC) is a heterogeneous disease, however there is limited information available regarding molecular classification and correlation with long term clinical outcome. Methods: Over the period of 11 years (2008 to 2018) totals 435 patients of colorectal cancer were reported and their tumour blocks and complete set of clinical information was available for 201 patients. Immunohistochemistry was done for ER, PR, HER 2-neu, Ki-67, Bcl-2, E-Cadherin, P53, CEA, EGFR, and VEGF. PDL1, CDX-2 and CK 20. The biological pattern characterized by partitioned clustering method as described using R software. Survival analysis was done by using Kaplan Meier method. Results: There were 201 patients including 54.7% male and females were 45.3 %. Median survival was 28 months. Cluster analysis showed four novel clusters (Table), with major difference based on Ki67, CDX2 and p53. These classes showed difference in median survival, where common class 1 showed higher survival while common cluster 4 showed poor survival. Conclusions: There are at least four distinct molecular classes of colorectal cancer which can be potentially utilized in clinical practice. Pattern of Novel molecular classification of colorectal cancer and correlation with long term survival.[Table: see text]